Investing.com - Summit Therapeutics PLC reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Summit Therapeutics PLC announced earnings per share of $-0.140 on revenue of $220K. Analysts polled by Investing.com EPS of $-0.260 on revenue of $0.00.
Summit Therapeutics PLC 's are down 28.9% and is trading at $0.986 , still down 82.97% from its 52 week high of $5.79 set on Wednesday, November 17, 2021.
Summit Therapeutics PLC shares lost 3.32% to trade at $0.986 in intra-day trade the report.
Summit Therapeutics PLC follows other major Healthcare sector earnings this month
Summit Therapeutics PLC's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar